RSV Vaccine For Infants Faces Challenges Throughout Rollout: “As Paediatricians, We’re Angry”
RSV Vaccine For Infants Faces Challenges Throughout Rollout: “As Paediatricians, We’re Angry” The respiratory syncytial virus (RSV) season is in full swing, and physicians are hoping that this year’s new vaccine to protect young children from the virus will reduce the number of cases. Some paediatricians, though, are having trouble procuring supplies. The Beyfortus antibody injection, manufactured by AstraZeneca and Sanofi, has received CDC and FDA approval to prevent respiratory syncytial virus in infants from birth to 8 months of age or in children up to 24 months of age with significant risk factors. The most common reason for hospital admissions for children under the age of one is respiratory syncytial virus (RSV). Paediatricians were hopeful that the medication could help reduce instances following a record year in 2022, according to Dr. Lauren Fitzpatrick, medical director of the paediatric unit at Luminis Health Anne Arundel Medical Centre. “We thought th...